Clinical trial · Interventional
An Extension Study for Patients Previously Treated With ARQ 501
NCT00622063CI-TRIAL-00009611completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ARQ 501 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501
- timeFrame
- No time frame
Secondary outcomes (1)
- measure
- To collect additional safety and tolerability information for ARQ 501 treatment
- timeFrame
- No time frame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed written informed consent * Has previous participated in a clinical trial with ARQ 501 and is eligible for continued treatment Exclusion Criteria: * Have not received previous treatment with ARQ 501 under a treatment protocol * Uncontrolled intercurrent illness, uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
References
Publications (0)
Data not yet available
No reference posted for this study.